Research shows that gut-targeting treatments may lower infection risk in intensive care patients, but neither approach significantly reduced deaths. A Gram Research analysis of 38 trials with 25,390 patients found that antibiotic gut decontamination was linked to about 50% lower pneumonia risk, while prebiotic and synbiotic supplements were linked to 30% lower risk.
Patients in intensive care units (ICUs) are often very sick and at high risk of infections, especially pneumonia. Researchers have tested two opposite strategies to protect them. One uses antibiotics to clear out harmful gut germs, called selective digestive decontamination. The other adds helpful microbes through prebiotics, probiotics, or synbiotics. According to research reviewed by Gram, this systematic review and meta-analysis pooled 38 randomized trials with 25,390 patients. Neither strategy significantly lowered the risk of death compared with standard care or placebo. Both appeared to reduce infections, with the strongest signal for pneumonia. Pneumonia risk was about half with antibiotic decontamination and about 30% lower with the helpful-microbe approaches. The included studies varied widely, so these results should be read as promising rather than settled.
Key Statistics
A 2026 meta-analysis of 38 randomized trials involving 25,390 adults in intensive care found that neither antibiotic gut decontamination nor helpful-microbe supplements significantly reduced the risk of death.
The same 2026 meta-analysis found that antibiotic gut decontamination was linked to a 50% lower risk of pneumonia in ICU patients (relative risk 0.50), while prebiotics and synbiotics were linked to a 30% lower risk (relative risk 0.70).
Across nine trials with 19,907 ICU patients, antibiotic gut decontamination was associated with a 24% lower risk of acquired infections compared with standard care or placebo (relative risk 0.76).
The Quick Take
- What they studied: Can treatments that change the germs in the gut, either by removing harmful germs with antibiotics or by adding helpful microbes, protect intensive care patients from infections and death?
- Who participated: The review combined results from 38 randomized trials. Nine trials tested antibiotic gut decontamination and included 19,907 adults. Twenty-nine trials tested prebiotics, probiotics, or synbiotics and included 5,483 adults. All participants were adults receiving intensive care.
- Key finding: Neither approach significantly reduced deaths. Antibiotic gut decontamination lowered pneumonia risk by about half (relative risk 0.50, meaning roughly 50% fewer cases), and helpful-microbe supplements lowered pneumonia risk by about 30% (relative risk 0.70). The range of uncertainty was wide, especially for the antibiotic approach.
- What it means for you: If you or a loved one is in intensive care, these findings give doctors more options to discuss, but they are not a reason to start any gut treatment on your own. Decisions about antibiotics or supplements in an ICU should be made with the care team, who can weigh the benefits against risks such as antibiotic resistance.
The Research Details
This study is a systematic review and meta-analysis. A systematic review is a careful search for all relevant studies on a topic using set rules, so that the results are not picked selectively. A meta-analysis then combines the numbers from those studies into one overall estimate, which is usually more reliable than any single trial.
The researchers searched PubMed for randomized controlled trials published between 2000 and 2025. In randomized trials, patients are assigned to a treatment or to a comparison group by chance, which helps prevent bias. To be included, studies had to enroll adult ICU patients, test either antibiotic decontamination or helpful-microbe supplements against standard care or a placebo (an inactive pill or substance), and report deaths or infections.
The team used a statistical method called random-effects modeling. This approach assumes that the studies differ from one another in real ways, such as in patient groups, doses, and settings, and it builds that variation into the final estimate.
Because few trials have directly compared antibiotic decontamination with helpful-microbe supplements, the researchers could not test the two head to head. Combining the trials of each approach, and comparing the pooled results against the same kinds of control groups, is the most practical way to see how the two strategies stack up.
Randomized trials are the strongest type of evidence for treatments, so restricting the review to them makes the findings more trustworthy than a review that mixed in weaker study designs.
Strengths include a clearly defined search, a focus on randomized trials, and a large combined group of about 25,000 patients. Readers should know that the studies were quite different from one another, especially the helpful-microbe trials, which tested many different products, doses, and timings. The estimates for pneumonia from antibiotic decontamination were also based on a relatively small number of events, so the range of uncertainty is wide. The abstract lists a total sample of 907 in the metadata, but the study’s own description of its included trials totals 25,390 patients, and the larger figure is used here.
What the Results Show
Neither antibiotic decontamination nor helpful-microbe supplements significantly reduced deaths in ICU patients. For antibiotic decontamination, the pooled relative risk for death was 0.96 (95% confidence interval 0.88 to 1.05), which means there was no clear difference from standard care or placebo. For prebiotics, probiotics, and synbiotics, the relative risk was 0.93 (95% confidence interval 0.87 to 1.00), which was also not a statistically significant change.
For infections overall, antibiotic decontamination was linked to a 24% lower risk of ICU-acquired infections (relative risk 0.76, 95% confidence interval 0.60 to 0.98). Helpful-microbe supplements were linked to an 18% lower risk, but that result was not statistically significant (relative risk 0.82, 95% confidence interval 0.64 to 1.05). The researchers did not find a statistically significant difference between the two approaches on overall infections.
Pneumonia showed the clearest signal. Antibiotic decontamination was linked to a 50% lower pneumonia risk (relative risk 0.50, 95% confidence interval 0.26 to 0.96). Prebiotics and synbiotics were linked to a 30% lower risk (relative risk 0.70, 95% confidence interval 0.54 to 0.90). A relative risk below 1 means fewer cases in the treatment group than in the comparison group.
The overall message is that both strategies appear to reduce infections, particularly pneumonia, which is one of the most common and serious infections in intensive care. However, lowering infections did not translate into fewer deaths in the pooled data. This suggests that preventing infections alone may not be enough to change survival for critically ill patients, who often face many other serious problems at the same time.
The authors describe the infection findings as similarly promising for both approaches. Given the wide ranges of uncertainty, the true effects could be smaller or larger than these estimates.
Earlier work on gut-focused strategies in intensive care has reported mixed results, with some trials finding fewer infections and others finding no benefit. This review brings those separate trials together and suggests that protection against infections is the most consistent benefit, while survival benefits have not appeared in the pooled data. The finding that antibiotic decontamination and helpful-microbe supplements look similar on infections also helps explain why the field has debated which approach is better.
The biggest limitation is variation between studies. The helpful-microbe trials used different products, doses, timing, and patient groups, which makes it hard to know which specific supplement, if any, works best. The pneumonia estimate for antibiotic decontamination has a very wide range (0.26 to 0.96), so the true benefit could be much smaller than the headline number. Because the two approaches were not compared directly in head to head trials, the review can only suggest that they perform similarly. The review also included only studies in English-language databases searched through PubMed, which may have missed some research. Finally, the trials focused on adults in intensive care, so the findings may not apply to children or to people with milder illness.
The Bottom Line
Moderate confidence: Both antibiotic gut decontamination and helpful-microbe supplements appear to reduce ICU infections, especially pneumonia, so they are worth discussing with critical care teams as options. Moderate to low confidence: Neither approach has been shown to reduce deaths in ICU patients. Low confidence: Choosing one approach over the other, because the direct comparison is limited and the studies varied widely. Any use of these treatments should be guided by clinicians, not by self-experiment.
Critical care doctors, nurses, hospital infection control teams, and families of patients in intensive care may find these results useful when discussing options. Researchers designing future trials will also benefit. People who are healthy and not in intensive care should not apply these findings by starting antibiotics or specialized supplements to prevent infections, since the studies did not test that situation and antibiotics carry real risks, including antibiotic resistance.
In the studies reviewed, infection outcomes were measured during each patient’s ICU stay, which is often days to a few weeks. Death outcomes were measured over the course of the trials, which varied in length. Because the research concerns hospital care, benefits would be seen within the ICU stay, not over months or years.
Frequently Asked Questions
Does gut decontamination help prevent pneumonia in intensive care patients?
Research shows that selective digestive decontamination was linked to about 50% lower pneumonia risk in ICU patients (relative risk 0.50) across nine trials. The range of uncertainty was wide, so the true effect may be smaller. Doctors weigh this against antibiotic resistance risks before using it.
Do probiotics reduce the risk of dying in intensive care?
A 2026 meta-analysis of 29 trials with 5,483 ICU patients found that prebiotics, probiotics, and synbiotics did not significantly reduce deaths (relative risk 0.93). These supplements were, however, linked to a 30% lower pneumonia risk, which suggests benefits for infections rather than survival.
Which is better for preventing ICU infections, antibiotics or probiotics?
Both approaches appeared similarly promising for preventing infections in a 2026 meta-analysis of 38 trials. Antibiotic decontamination showed a stronger pneumonia signal, but the studies were too varied and too few in direct comparison to declare a clear winner.
Should I take probiotics to prevent infections if I am healthy?
This research studied adults in intensive care, not healthy people. The findings should not be used to start probiotics or antibiotics for infection prevention. Speak with a doctor or pharmacist about whether any gut-focused supplement fits your individual health needs.
Want to Apply This Research?
- Rather than tracking personal gut treatments, users who are caring for someone in an ICU can log the questions they plan to ask the care team each day, the infection-related updates they receive (such as pneumonia diagnosis or antibiotic start dates), and any side effects reported. This creates a clear, shareable record that makes conversations with clinicians more specific.
- Use the app to prepare a short question list before each care team update. Good starting questions include: Is gut decontamination or a supplement being considered for this patient, and why? What infection risks is the team watching for? What are the known side effects or risks of this option? Recording answers in the app helps families follow the plan over time.
- For people who are not in intensive care, the most useful long-term habit is supporting general gut health through a varied diet rich in fiber, fruits, vegetables, and fermented foods, while tracking any digestive symptoms or antibiotic courses with a doctor. Users should not use this research to decide on antibiotics or probiotics for infection prevention without medical advice. Review the app log with a clinician at regular check-ins.
This article summarizes a systematic review and meta-analysis for general education only. It is not medical advice and does not replace guidance from a qualified doctor or critical care team. The studies reviewed involved adults in intensive care, and antibiotic use carries risks, including antibiotic resistance. Do not start, stop, or change any antibiotic, probiotic, or supplement without speaking with a healthcare professional.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.